<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448212</url>
  </required_header>
  <id_info>
    <org_study_id>TS121-US103</org_study_id>
    <nct_id>NCT02448212</nct_id>
  </id_info>
  <brief_title>Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects</brief_title>
  <official_title>A Phase 1 Receptor Occupancy Study Using Positron Emission Tomography to Investigate Novel Ligand [11C]TASP0410699 Alone and Following Single Oral Dose Administrations of TS-121 in Healthy Adult (Male) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the binding of a novel tracer, [11C]TASP0410699,
      using Positron Emission Tomography (PET) scans with or without dosing of TS-121
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron emission tomography measure (receptor occupancy)</measure>
    <time_frame>Day 1 through Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of TS-121</measure>
    <time_frame>Day 1 through Day 3</time_frame>
    <description>Area under the plasma concentration (AUC) from time zero to time of last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of TS-121</measure>
    <time_frame>Day 1 through Day 3</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of TS-121</measure>
    <time_frame>Day 1 through Day 3</time_frame>
    <description>Time to attain cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite safety as assessed by clinical laboratory tests, 12-lead ECG, vital signs, adverse events and physical examinations</measure>
    <time_frame>up to Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PART 1 (Test/Retest)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 2 (PET Receptor Occupancy Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-121</intervention_name>
    <description>Oral</description>
    <arm_group_label>PART 2 (PET Receptor Occupancy Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]TASP0410699</intervention_name>
    <description>Intravenous radiotracer</description>
    <arm_group_label>PART 1 (Test/Retest)</arm_group_label>
    <arm_group_label>PART 2 (PET Receptor Occupancy Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <description>Imaging scanning procedure</description>
    <arm_group_label>PART 1 (Test/Retest)</arm_group_label>
    <arm_group_label>PART 2 (PET Receptor Occupancy Study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males 18 - 55 years of age (at time of initial informed consent)

          2. Body weight â‰¥ 50 kg

          3. Body Mass Index (BMI) 18 - 30 kg/m2

          4. Male subjects with partners of childbearing potential must agree to use appropriate
             and effective measures of contraception for 90 days following drug administration

        Exclusion Criteria:

          1. Prescription, over-the-counter or herbal medications, supplements, within 14 days
             before the study.

          2. Clinically significant abnormal electrocardiogram, physical examination, or
             hematology, biochemistry, hormone, or urinalysis values at screening &amp; baseline.

          3. Significant history &amp;/or presence of hepatic, renal, cardiovascular, hemodynamic,
             pulmonary, gastrointestinal, hematological, CNS, immunologic, ophthalmologic,
             metabolic, endocrine, or oncological disease or condition within last 5 years.

          4. Current use of tobacco or tobacco-containing products, recent history of alcohol or
             drug abuse OR positive urine screen for alcohol or controlled substances at screening
             or baseline.

          5. History &amp;/or current evidence of serologic positive results for hepatitis B or C, or
             HIV.

          6. Donation or acute loss of 450 milliliters or more of blood or plasma, within 60 days
             of the study.

          7. Any subject who has received treatment with a non-FDA approved drug within 30 days of
             study screening.

          8. Subjects who suffer from claustrophobia.

          9. Current, past, or anticipated exposure to radiation in the workplace or participation
             in other research studies involving ionizing radiation that would exceed the yearly
             dose limits for normal subjects.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Carson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shoji Yasuda</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical R&amp;D Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University PET Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>Receptor Occupancy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

